Answers are grounded in this paper and cite their sources.
As APC or KRAS mutations are currently identified as the most important targets for CRC therapy, this study proposes that 20q13.33 copy number gain and the associated chromosomal genes function as promising biomarkers for both early stage detection and targeted therapy of sporadic CRCs in the future.
No takes yet. Share an insight, caveat, or question.
Bui et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: